Different immunophenotypical apoptotic profiles characterise megakaryocytes of essential thrombocythaemia and primary myelofibrosis

Journal of Clinical Pathology

Volumn 62, Issue 4, 2009, Pages 331-338

  Florena, A M ^a   Tripodo, C ^a   Bernardo, A Di ^a   Lannitto, E ^a   Guarnotta, C ^a   Porcasi, R ^a   Ingrao, S ^a   Abbadessa, V ^a   Franco, V ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; CASPASE 3; DNA NUCLEOTIDYLEXOTRANSFERASE; FAS ANTIGEN; FAS LIGAND; HYDROXYUREA; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; TELOMERASE REVERSE TRANSCRIPTASE;

ADULT; AGED; APOPTOSIS; ARTICLE; BONE MARROW BIOPSY; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MEGAKARYOCYTE; MYELOID METAPLASIA; NICK END LABELING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; THROMBOCYTHEMIA; THROMBOSIS;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; BIOPSY; BONE MARROW; FEMALE; HUMANS; IMMUNOPHENOTYPING; IN SITU NICK-END LABELING; MALE; MEGAKARYOCYTES; MIDDLE AGED; PRIMARY MYELOFIBROSIS; PROGNOSIS; THROMBOCYTHEMIA, ESSENTIAL;

EID: 65849340870     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jcp.2007.054353     Document Type: Article

References (32)

1. Hoffman R, Prchal JT, Samuelson S, etal. Philadelphia chromosome-negative myeloproliferative disorders: biology and treatment. Biol Blood Marrow Transplant 2007;13(1 Suppl 1):64-72. (Pubitemid 46044119)
2. Vardiman JW, Brunning RD, Harris N. Chronic myeloproliferative diseases: Introduction. In: Jaffe ES, Harris N, Stein H, Vardiman JW (eds). WHO classification of tumours: tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press, 2001,17-19
3. Michiels JJ, Thiele J. Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera and idiopathic myelofibrosis (agnogenic myeloid metaplasia). Int J Hematol 2002;76:133-145 (Pubitemid 43020326)
4. Florena AM, Tripodo C, lannitto E, et al. Value of bone marrow biopsy in the diagnosis of essential thrombocythemia. Haematologica 2004;89:911-919 (Pubitemid 39049898)
5. BallaroB, Florena AM, Franco V, et al. An automated image analysis methodology for classifying megakaryocytes in chronic myeloproliferative disorders. Med Image Anal 2008;12:703-712
6. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-1790 (Pubitemid 40570926)
7. Tefferi A. Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era. Hematology Am Soc Hematol Educ Program 2006:240-245 (Pubitemid 43863139)
8. Levine RL, Wernig G. Role of JAK-STAT signaling in the pathogenesis of myeloproliferative disorders. Hematology Am Soc Hematol Educ Program 2006:233-239
9. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007;110:1092-1097 (Pubitemid 47281402)
10. Jensen MK, Riisbro R, Holten-Andersen MN, et al. Collagen metabolism and enzymes of the urokinase plasminogen activator system in chronic myeloproliferative disorders: correlation between plasma-soluble urokinase plasminogen activator receptor and serum markers for collagen metabolism. Eur J Haematol 2003;71:276-282 (Pubitemid 37179885)
11. Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol 2007;35:495-516. (Pubitemid 46911891)
12. Crist SA, Elzey BD, Ludwig AT, et al. Expression of TNF-related apoptosis-inducing ligand (TRAIL) in megakaryocytes and platelets. Exp Hematol 2004;32:1073-1081 (Pubitemid 39469931)
13. Zhang L, Zhao H, Sun A, et al. Early down-regulation of Bcl-xL expression during megakaryocytic differentiation of thrombopoietin-induced CD34+ bone marrow cells in essential thrombocythemia. Haematologica 2004;89:1199-1206 (Pubitemid 39390444)
14. Ghobrial IM, Witzig TE, Adjei AA. Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin 2005;55:178-194 (Pubitemid 40826487)
15. Goodsell DS. The molecular perspective: Bcl-2 and apoptosis. Oncologist 2002;7:259-260 (Pubitemid 34651231)
16. Goodsell DS. The molecular perspective: cytochrome c and apoptosis. Oncologist 2004;9:226-227 (Pubitemid 38452122)
17. Carobbio A, Finazzi G, Guerini V, et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood 2007;109:2310-2313 (Pubitemid 46425868)
18. Cervantes F, Alvarez-Larran A, Arellano-Rodrigo E, et al. Frequency and risk factors for thrombosis in idiopathic myelofibrosis: analysis in a series of 155 patients from a single institution. Leukemia 2006;20:55-60.
19. Thiele J, Kvasnicka HM, Facchetti F, et al. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 2005;90:1128-1132 (Pubitemid 41323513)
20. Kvasnicka HM, Thiele J. Classification of Ph-negative chronic myeloproliferative disorders - morphology as the yardstick of classification. Pathobiology 2007;74:63-71. (Pubitemid 46985278)
21. Mesa RA, Hanson CA, Li CY, et al. Diagnostic and prognostic value of bone marrow angiogenesis and megakaryocyte c-Mpl expression in essential thrombocythemia. Blood 2002;99:4131-7.
22. Mesa RA, Hanson Ca, Rajkumar V, et al. Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia. Blood 2000;96:3374-80.
23. O'Brien DI, Nally K, Kelly RG, at al. Targeting the Fas/Fas ligand pathway in cancer Expert Opin Thar Targets 2005;9:1031-1044 (Pubitemid 41488838)
24. Ciurea SO, Merchant D, Mahmud N, at al. Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis. Blood 2007 110;3:986-993 (Pubitemid 47267438)
25. Rossi D, Gaidano G. Messengers in cell death: apoptotic signals in health and disease. Haamatologica 2003;88:212-218 (Pubitemid 37101499)
26. Liu FT, Goff LK, Hao JH, at al. Increase in the ratio of mitochondrial Bax/Bcl-Xl induces activation in human leukemic K562 cell line. Apoptosis 2004;9:377-384 (Pubitemid 38981512)
27. Tenedini E, Fagioli ME, Vianelli N, at al. Gene expression profiling of normal and malignant CD34-derived megakaryocyte cells. Blood 2004;104:3126-3135 (Pubitemid 39507126)
28. Farwell DG, Shera KA, Koop JI, at al. Genetic and epigenetic changes in human epithelial cells immortalized by telomerase. Am J Pathol 2000;156:1537-1617
29. Bock O, Serinsoz E, Schlue J, at al. Different expression levels of the telomerase catalytic subunit hTERT in myeloproliferative and myelodysplastic diseases. Lauk Ras 2004;28:457-460 (Pubitemid 38453057)
30. Barbui T, Barosi G, Grossi A, at al. Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haamatologica 2004;89:215-232 (Pubitemid 38796497)
31. Teofili L, Pierconti F, Di Febo A, atal. The expression pattern of c-mpl in megakaryocytes correlates with thrombotic risk in essential thrombocythemia. Blood 2002;100:714-717 (Pubitemid 34761144)
32. Finazzi G, Rambaldi A, Guerini V, at al. Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status. Haamatologica 2007;92:135-136 (Pubitemid 46232672)